PAIN RELIEVER & SLEEP AID TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
30-09-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM
Tillgänglig från:
APOTEX INC
ATC-kod:
M01AE57
INN (International namn):
NAPROXEN AND DIPHENHYDRAMINE
Dos:
25MG; 220MG
Läkemedelsform:
TABLET
Sammansättning:
DIPHENHYDRAMINE HYDROCHLORIDE 25MG; NAPROXEN SODIUM 220MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
OTC
Terapiområde:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0257270001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2020-10-08
Produktens egenskaper
Page 1 of 47
PRODUCT MONOGRAPH
PAIN RELIEVER & SLEEP AID
Naproxen Sodium 220 mg and Diphenhydramine Hydrochloride 25mg Tablets
Apotex Inc.
150 Signet Drive
Toronto, Ontario
Canada M9L 1T9
Date of Preparation:
September 30, 2020
Control No. 230683
Page 2 of 47
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
...........................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
12
DOSAGE AND ADMINISTRATION
.......................................................................................................
14
OVERDOSAGE...........................................................................................................................................
15
ACTION AND CLINICAL
PHARMACOLOGY......................................................................................
15
STORAGE AND STABILITY
...................................................................................................................
18
SPECIAL HANDLING INSTRUCTIONS
................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
18
PART II: SCIENTIFIC INFORMATION
.............................................................................................
20
PHARMACEUTICAL INFORMATION
........
Läs hela dokumentet
